论文部分内容阅读
应用三苯氧胺（ＴＡＭ）抑制实验对３９例乳腺癌ＥＲ（＋）病人进行了检测。其中２４例ＴＡＭ抑制实验有不同程度的抑制阻断，抑制率从１０％～１００％。其余１５例ＥＲ（＋）者，而ＴＡＭ抑制率为零。不同组织学类型ＴＡＭ抑制率实验似有差异，髓样癌的阳性检出率较浸润性导管癌高。从理论上讲，ＴＡＭ在部分ＥＲ（＋）病人体内，并不能阻断Ｅ２与受体结合，因而对ＴＡＭ抑制实验阴性的病人，ＴＡＭ不能起到治疗效果。因此建议进行激素受体测定时，加测ＴＡＭ抑制实验，以指导临床用药。
Tamoxifen (TAM) inhibition test was used to detect ER (+) in 39 cases of breast cancer. Twenty-four TAM inhibition experiments had different degrees of inhibition and the inhibition rate was from 10% to 100%. The remaining 15 cases of ER (+), and TAM inhibition rate is zero. Different histological types of TAM inhibition rate test seems to be different, and the positive detection rate of medullary carcinoma is higher than that of invasive ductal carcinoma. In theory, TAM does not block the binding of E2 to the receptor in some patients with ER(+). Therefore, TAM does not have a therapeutic effect in patients with negative TAM inhibition test. Therefore, it is recommended that when the hormone receptor assay is performed, TAM inhibition test should be added to guide clinical medication.